Chemistree Gains Access to Medical CBD Market Through Strategic Investment into The Physician’s Choice CBD

Chemistree

Chemistree Technology Inc. (CSE:CHM) (OTCQB:CHMJF) released some exciting news Monday that will expand its CBD portfolio and give the company exposure to the medical CBD market. Chemistree announced that it has entered into a funding agreement with The Physician’s Choice CBD (PCCBD), a doctor-led medical cannabis company with nine hemp-derived CBD products under its belt.

The Physician’s Choice CBD’s leaders, Dr. Julian Grove and Dr. Peter Kubitz, are both board-certified practicing physicians who specialize in pain management and have over 15 years of experience in private practice. PCCBD has been dedicated to the research, development, and utilization of high-quality hemp-derived cannabidiol combined with well-studied and effective supplements to aid in a variety of ailments, from pain and inflammation to sleep.

The investment is a big win for Chemistree, a Vancouver-based investment company that is focused on making strategic investments in the US cannabis sector.

“This investment in The Physician’s Choice CBD is a great opportunity for Chemistree,” said Karl Kottmeier, Chemistree’s President, in a statement. “Their collective education and practical experience are industry-leading and their commitment to the health of their patients and to developing real solutions to pain management with cannabidiol-based supplements is truly inspiring.”

Enter Your E-mail Address To Subscribe

* indicates required
 

The Physician’s Choice CBD was only established in 2018, yet it has already developed a line of nine full-spectrum CBD products, which are available online and also distributed through healthcare providers across the US. The products are already doing well on the market, with the company securing approximately $150,000 in sales in its first quarter.

PCCBD set out to tackle the difficulties that come with treating patients who suffer from chronic pain with prescription pain medication, as long-term use can lead to a myriad of other problems including side effects, end-organ damage, and the potential for addiction and abuse. Outside of pain medication, the doctors also offered patients physical therapy, interventional therapies, and complementary treatments such as massage, acupuncture, chiropractic, and naturopathic medicine. Unfortunately, they found that this was often not enough.

“Managing various pain syndromes with medications that do not exacerbate severe medical conditions and behavioral risk factors is an ongoing challenge for medical professionals,” explained Dr. Grove. “This has been a driving force in the development of a product line of cannabidiol products, aiding in the management of specific pain syndromes and improve a sense of well-being.”

The investment into PCCBD will give Chemistree an ownership stake in the company, provide exposure to a new industry and further expand its access to the US cannabis market.

“The investment we are making into PCCBD gives us exposure to an entirely new industry and we are excited to assist wherever we can to see PCCBD continue to grow its sales and product offerings into a multi-state success,” said Kottmeier.

Chemistree’s investment in PCCBD comes a month after the company closed a prospective offering and concurrent private placement for a total of $10.8 million CAD. The company said it would use the funds to expand its facilities in Washington, launch the Sugarleaf brand in California, and continue the licensing, development, and build-out of its Desert Hot Springs property.

Chemistree was also recently granted a conditional use permit by the City of Desert Hot Springs for its 9.55-acre property, which will allow cultivation in two 128,000 square foot greenhouses and access to an additional 40,000 square foot building for the processing, manufacturing, and distribution of cannabis products.

Chemistree’s share price reacted favorably to the news. By 1:oo pm EST, Chemistree’s share price was $0.69 CAD on the Canadian Securities Exchange, up $0.02 (+2.99%).

Please See Disclaimer

Featured Image: Canva

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Chemistree Technology Inc. Market Jar Media Inc. has or expects to receive the following amounts from Native Ads Inc. in the amount of one hundred eighty three thousand, twenty US dollars for 25 campaign days (19 business days). In addition, Market Jar was re-engaged by Native Ads for a period of 60 campaign days (44 business days) in the amount of four hundred thousand US dollars.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com .

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.